Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
Last Updated: Friday, February 11, 2022
This New England Journal of Medicine article, published after the presentation of the data at the 2021 American Society of Hematology Annual Meeting, provides more information on the phase 3 POLARIX trial of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone compared with R-CHOP among patients with previously untreated intermediate-risk or high-risk DLBCL.
Advertisement
News & Literature Highlights
